查詢結果分析
相關文獻
- Survival Benefit of Uracil-Tegafur (UFT) for AJCC 7th Pathologic Stage IB Non-Small Cell Lung Cancer Patients: A Propensity Score Matching Study
- Recent Advances in Systemic Therapy for Non-Small Cell Lung Cancer in Elderly Patients
- Revisiting Squamous Cell Carcinoma of the Lungs--A Disease Given Less Attention
- Pemetrexed Followed by Docetaxel or a Reverse Sequence in Non-Small-Cell Lung Cancer
- Non-Small-Cell Lung Cancer in Patients Older than Eighty Years
- 非小細胞肺癌治療之風雲再起
- 非小細胞肺癌術前輔助性化學治療的經驗
- 5-HT3阻斷劑用於化療止吐之療效及經濟學觀點評估
- The Role of Radiotherapy for Advanced Non-Small Cell Lung Cancer
- Differential Display of mRNA in Human Lung Tissue and in Non-Small Cell Lung Cancer: A Preliminary Report
頁籤選單縮合
題 名 | Survival Benefit of Uracil-Tegafur (UFT) for AJCC 7th Pathologic Stage IB Non-Small Cell Lung Cancer Patients: A Propensity Score Matching Study=友復(UFT)對於Stage IB非小細胞肺癌病患術後的生存益處評估 |
---|---|
作 者 | 吳青峰; 傅瑞英; 王志偉; 劉永恆; 謝明儒; 吳青陽; 吳怡成; 劉會平; | 書刊名 | 胸腔醫學 |
卷 期 | 30:4 2015.08[民104.08] |
頁 次 | 頁191-200 |
分類號 | 418.31 |
關鍵詞 | 非小細胞肺癌; 分期IB; 友復膠囊; 化療; Non-small cell lung cancer; Stage IB; Uracil-tegafur; Chemotherapy; |
語 文 | 英文(English) |
中文摘要 | 目的:對於 Stage IB的病患使用友復膠囊作為術後追加的化學治療在台灣以及日本都被廣泛的討論及使用,本篇論文所要討論的就是對於第七版的 AJCC分期的 IB病患,使用友復膠囊對於病患生存的益處評估。 方法:我們回溯性的分析 220位原本在第六版的 AJCC分期裡 IB的病患重新依據第七版的 AJCC分期條件及利用傾向分數( propensity score)1:4作為分類的方式選出 130位病患分成兩組:術後使用友復膠囊的病患 26位,沒有使用友復膠囊的病患 104位,對於這整群的 IB病患做預後危險因子分析:包括年紀、性別、手術方式、細胞種類、臟器肋膜的侵犯,以及血管淋巴管侵犯。 結果:根據本文的統計結果,腫瘤大小小於 3公分跟接受友復( UFT)治療的非小胞肺癌 IB病患有較好的存活率。在多重變數分析中,腫瘤大於 3公分為負向存活指標,(勝算比 odds ratio=3.496; 95% confidence interval, 1.49-8.20),有服用友復的 IB病患則有較好的存活率( odds ratio=0.180; 95% confidence interval, 0.049-0.660),如果大於 3公分的病患接受過友復膠囊治療,存活率也較無接受治療的病患好(p=0.041)。 結論:總結而言,對於 IB病患術後服用友復( UFT)的確能增加病患的生存率,且對於大於 3公分的 IB病患也能增加術後的存活時間。 |
英文摘要 | PURPOSE: Adjuvant chemotherapy with uracil-tegafur (UFT) is widely used for pathologic stage IB (pIB) non-small cell lung cancer (NSCLC) in Taiwan and Japan. The aim of this study was to identify the survival benefit for patients with and without UFT treatment. METHODS: We performed a retrospective review of 220 patients with stage pIB disease (using the 6th American Joint Committee on Cancer (AJCC 6th) Cancer Staging Manual) who underwent lung resection from January 2005 to July 2012. All patients were reclassified using the AJCC 7th cancer staging system, and 130 matched subjects were included. Using a propensity score matching method (1:4 match), patients with stage pIB disease were divided into 2 groups (UFT: 26, Non-UFT: 104). The oral dose of UFT was 400 mg/body. Multiple risk factors were analyzed, including age, gender, surgical method, cell type, visceral pleural invasion, and angiolymphatic invasion. The 2 study groups were well matched with respect to age, gender, surgical method (video-assisted thoracoscopic surgery or open thoracotomy), and pathological parameters, including cell type, visceral pleural invasion, and angiolymphatic invasion. RESULTS: A tumor diameter greater than 3 cm was a poor prognostic factor for overall survival of patients with stage pIB NSCLC. The survival rate was significantly higher in the UFT group than in the surgery-alone group. Multivariate analyses revealed that a tumor diameter >3 cm (odds ratio=3.496; 95% confidence interval, 1.49-8.20) and use of UFT (odds ratio=0.180; 95% confidence interval, 0.049-0.660) were predictive of overall survival. The overall survival of patients with a tumor diameter >3 cm who were treated with UFT was better than the overall survival of those not treated with UFT. (p=0.041) CONCLUSION: In conclusion, UFT treatment was shown to prolong the overall survival of patients with newly diagnosed stage pIB NSCLC in our study. In addition, patients with a tumor diameter >3 cm had poor overall survival, but could obtain a survival benefit after completing 2 years of UFT treatment. |
本系統中英文摘要資訊取自各篇刊載內容。